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Much has been made over the past decade of the
potential for genetics to advance our understanding of
the pathogenesis of type 2 diabetes and to ‘revolutionise’
management of this condition [1]. Others have argued that
these claims are premature [2]; indeed, some have
questioned the contribution of genetic predisposition to
the pathogenesis of common forms of type 2 diabetes [3].
In the case of relatively uncommon monogenic and
syndromic forms of diabetes, such as maturity onset
diabetes of the young (MODY) and neonatal diabetes,
identification of rare causal mutations has delivered both
knowledge and clinical translation [4, 5]. In contrast,
progress in unravelling the genetic architecture of more
typical, common, multifactorial type 2 diabetes has been
painfully slow [6]. The reasons have been well-rehearsed
[7]. The complex web of susceptibility factors—genetic,
environmental, social—that contributes to individual risk of
developing type 2 diabetes means that most predisposing
genetic variants will have only a modest marginal impact
on disease risk. The majority of genetic studies performed
to date have simply had insufficient power to uncover these
reliably [7]. The few type 2 diabetes-susceptibility variants
convincingly demonstrated—notably the P12A variant in
PPARG and E23K in KCNJ11 [8, 9]—have only modest
effects on disease risk (odds ratios ~1.2), far too small to
offer (either individually or in combination) clinically
useful predictive testing. Since these variants lie within
genes whose products are already known to be therapeutic
targets, these particular discoveries have also had limited
capacity to deliver novel pathophysiological insights.
Among those working on the genetics of type 2 diabetes,
there was growing apprehension that these two genes might
be providing a representative view of the genetic architec-
ture of type 2 diabetes.
However, recent revelations concerning a novel type 2
diabetes-susceptibility gene (encoding the transcription fac-
tor, TCF7L2 [‘7-like 2’]) show that this is definitely not the
case. As twopapersin this issueof Diabetologia demonstrate
[10, 11], common variants in this gene have a marked and
reproducible effect on type 2 diabetes risk, identifying
sizeable groups of individuals who differ up to twofold in
their risk of developing type 2 diabetes, purely as a result of
variation at a single nucleotide position within TCF7L2.
These studies in Dutch [10] and Indian [11] samples are
the latest in a series of reports confirming the powerful
effect of TCF7L2 variation on type 2 diabetes-risk which
have followed the initial publication from Iceland in early
2006 [12]. Researchers at Decode Genetics seeking the
cause of a previously-identified linkage signal on chromo-
some 10q [13] found strong associations between type 2
diabetes status and TCF7L2 variants that they were able to
replicate in samples from the USA and Denmark. The effect
size in this initial report appeared substantial (each
additional copy of the risk allele was associated with an
odds ratio of ~1.5), and the strength of the association was
impressive (p~10
−18 overall).
Since the initial report in early 2006, the freezers of
diabetes researchers worldwide have been raided and many
tens of thousands of samples typed for these same variants.
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original findings. In UK samples for example, the same
TCF7L2 susceptibility variants were associated with a per-
allele odds ratio of ~1.4 [14]. As in the original report, there
was clear evidence of a gene dosage effect, such that the
10% of individuals with two copies of the susceptibility
allele were at almost twice the risk of developing diabetes
as those with none. In participants from the Diabetes
Prevention Program, the same TCF7L2 variants were
associated with increased rates of progression from IGT to
diabetes (with a hazard ratio of 1.55 between homozygote
groups) [15]. Further replications have appeared from
analyses in subjects of Amish [16], Finnish [17], French
[18]a n dU S[ 19, 20] origin. Little wonder that one
colleague was moved to describe TCF7L2 as ‘the biggest
story in diabetes genetics since HLA’.T h es p e e do f
confirmation and reproducibility of the findings has
certainly been unprecedented.
All very well, you may say, that must be great for the
geneticists, but what does all of this mean for our
understanding of diabetes? And what difference will this
make to the clinical management of this condition? In truth,
it is far too early to offer an authoritative answer to such
questions, but here are three immediate lessons.
Lesson 1: Type 2 diabetes-susceptibility variants
with large effect sizes do exist and can be found
The increase in risk of type 2 diabetes associated with the
TCF7L2 variant alleles so far identified is substantially
greater than that associated with variants in the other
confirmed type 2 diabetes-susceptibility genes (PPARG,
KCNJ11). The limited data so far available from more
comprehensive genotyping efforts across the gene [12, 17,
20] suggest that the SNPs reported in the Icelandic study
(and typed in most subsequent studies) have the strongest
association with type 2 diabetes. However, it remains
entirely possible that there are additional (or alternative)
variants within the gene which carry even greater risk. If so,
current estimates that the population risk attributed to
TCF7L2 variants lies between 10 and 25% may need to
be revised upwards [10–12, 14–20]. Certainly, no func-
tional significance has been attributed to the TCF7L2
variants implicated so far, all of which are intronic.
Evidence that the same associations are apparent in non-
European samples [11] increases the chances that these
SNPs are aetiological, though studies in populations with
more divergent linkage disequilibrium structures (particu-
larly those of African origin) will be most informative in
this regard. Further, data from both the Icelandic [12] and
UK [14] studies make it clear that the variants concerned
are not responsible for the previously reported linkage
signals on chromosome 10 [13, 21]. Either the detection of
TCF7L2 within the region of the linkage signal was
serendipitous, or else other (most likely rare, highly
penetrant) variants within the gene also contribute to
disease risk. Deep resequencing of the gene should help
to resolve this question.
From a methodological point of view, identification of a
type 2 diabetes-susceptibility variant with such a consider-
able effect size has several important ramifications. First, it
speaks to the value of adequate sample size and replication
as mechanisms for delivering robust findings [22]. Unusu-
ally, the effect size at TCF7L2 is such that the association
signal can be detected with only a few hundred samples:
ensuring adequate power becomes even more essential
when seeking to validate variants with lesser effect sizes.
We can expect these to be far more numerous than variants
like TCF7L2 [7]. Second, the identification of TCF7L2 is
testament to the validity of susceptibility-gene discovery
through indirect linkage disequilibrium-mapping ap-
proaches [23]. And third, evidence that such powerful
effects exist augurs well for the early success of ongoing
efforts to exploit genome-wide association mapping as a
tool for further gene discovery efforts. The multiple-testing
penalty implicit in such studies means that only effect sizes
on this scale are likely to emerge from initial rounds of
analysis within individual genome-wide association data
sets [23].
Lesson 2: Since we know so little about TCF7L2, novel
insights into diabetes pathogenesis are guaranteed
At this early stage, precious little is known about the
normal role of TCF7L2, or how dysfunction predisposes to
diabetes. The gene seems to be widely expressed [18] and
the transcription factor product is known to be involved in
the Wnt signalling cascade. Current evidence strongly
supports the idea that the predominant effect of TCF7L2
dysfunction on type 2 diabetes development is mediated
through impairment of insulin secretion [11, 15–17, 20], a
finding that would be consistent, for example, with the
known effects of other (non-homologous) TCF genes
(TCF1 [also known as HNF1A] and TCF2 [also known as
HNF1B]) that are causal for MODY [4]. Whether or not the
reduction in insulin secretion reflects a defect in the
enteroinsular axis (early speculation—as yet unsupported
by experimental data—p o i n t e dt oi m p a i r e dr e l e a s eo f
glucagon-like peptide-1 (GLP1) from enteroendocrine cells
[12]), reduced beta cell mass (for example, through
impaired pancreatic development), or intrinsic beta cell
dysfunction, remains, as yet, unanswered. One intriguing
observation reported across several data sets [12, 15, 18]i s
that in cases (but not controls), the type 2 diabetes-
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reduced BMI. Whether this reflects an ascertainment effect
(i.e. the reduction in beta-cell function is so profound that
carriers tend to develop type 2 diabetes at a lower BMI than
otherwise) or genuine biology (e.g. the chronic effects of
beta cell insufficiency, given insulin’s anabolic role) is
another interesting question. Finally, the critical role of
TCF7L2 in glucose homeostasis points out the need for
improved understanding of the role played by Wnt
signalling in metabolic processes, and exploration of the
possibilities for novel therapeutic modalities. TCF7L2
variants provide an experiment of nature that will allow
these and other vital questions about diabetes pathogenesis
to be addressed.
In addition to the two studies referred to earlier [10, 11],
this issue of Diabetologia contains two letters which
address the potential contribution of TCF7L2 to the
development of other forms of diabetes [24, 25]. Cauchi
and colleagues [24] asked whether rare mutations within
TCF7L2 might be contributing to the causation of mono-
genic forms of diabetes such as MODY and neonatal
diabetes. Growing evidence of overlap in the genes
involved in monogenic and multifactorial forms of diabetes
[6] made this an excellent proposition. However, despite
careful resequencing of all potential exons and intron–exon
junctions of TCF7L2 in 28 subjects with neonatal diabetes,
and 17 with MODY (in whom other known causal genes
had been excluded) no such mutations were uncovered. A
second study, limited to neonatal diabetes alone, reached
similar conclusions [14].
Field and colleagues [25] used the substantial resources
available to the Cambridge group to determine whether or
not the TCF7L2 variants implicated in type 2 diabetes had
any discernible impact on risk of developing type 1
diabetes. Their study, involving almost 14,000 subjects,
conclusively demonstrates that they do not. This finding
has implications for theories (such as the accelerator
hypothesis) that propose a common aetiological basis for
both type 1 and type 2 diabetes [26].
Lesson 3: The odds for successful translation of genetic
information into clinical management have shortened
considerably
Though it is easy to regard TCF7L2 as having a ‘large’
effect because of its detectability in quite modest sample
sizes, this does not translate into immediate clinical utility.
A genetic test based around TCF7L2 alone would lack
sufficient sensitivity and specificity to be useful for risk
prediction, in unselected populations at least [27]. But how
might TCF7L2 variants fare in combination with other
genetic and clinical markers of prediction? These are early
days, but there are cautious grounds for optimism. Recent
theoretical studies have emphasised that as few as 20
susceptibility variants on the scale of those in TCF7L2,
PPARG and KCNJ11 may suffice to explain as much as
50% of the burden of disease [28]. Empirical data gathered
on more than 6,000 UK samples typed for the susceptibility
variants in these three genes have recently shown that it is
possible, using genetic information alone, to identify
reasonably sized subgroups of individuals who differ more
than threefold in diabetes risk [29].
The trade-off between sensitivity and specificity for such
predictive tests can best be summarised using a so-called
receiver-operating characteristic (ROC) curve. The area
under such a curve is widely used as an index of the
discriminative accuracy of a diagnostic test [30]. Practically
speaking, this index denotes the frequency with which the
test of interest correctly assigns diagnostic status when
presented with two individuals, one of whom has, and other
does not have, the disease of interest. The measure
therefore ranges from 50% (no discrimination whatsoever;
a random call) to 100% (perfect discrimination). In UK
samples, the variants in PPARG, KCNJ11 and TCF7L2 are
jointly capable of generating a discriminative value of
approximately 58% [29]. Though short of the levels usually
considered consistent with clinical utility (at least 75%),
this value is the product of the fruits harvested from the
very small proportion of the genome (a few percent) so far
subjected to detailed examination in adequately powered
data sets.
Over the next year, large-scale genome-wide association
scan data being generated by several groups worldwide will
extend that coverage (for common SNPs at least) to close to
70%. We will know, fairly soon, how many other
‘TCF7L2s’ there are likely to be. These first, close-to-
comprehensive views of the association landscape will help
to settle the extent to which such common susceptibility
variant information can be applied to clinically useful risk
prediction. In parallel, studies that address the consequen-
ces of common variation for other aspects of clinical
management, such as the prediction of complication risk
and the response to prophylactic and/or therapeutic inter-
ventions [15], will establish the potential for other routes to
clinical translation.
In recent years, research into the genetic basis of
complex traits had been growing increasingly introspective,
concerned with the limitations of then-current experimental
approaches and the bewildering morass of conflicting and
inconsistent results. The rapid elevation of TCF7L2 from
mere candidate to presidential status (a rise enabled by the
availability of large sample sets from diverse populations
and rapid, accurate genotyping), has meant that years of
debate about the validity of TCF7L2 as a diabetes-
susceptibility gene have been avoided. As a result, the full
Diabetologia (2007) 50:1–4 3panoply of biochemical, genomic, epidemiological and
other tools is now being deployed to define the pathogenic
mechanisms through which it operates and to explore the
translational potential. The hope is that the current round of
genome-wide association studies will deliver other new
diabetes-susceptibility genes for researchers to play with in
the years to come.
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